Hydrogen in Cerebrovascular Disease
Translational Neurology and Neurosurgery · 2026
DOI: 10.2738/tnn.2026.0008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Neurology and Neurosurgery, 2026. Verfasst von Shiqin Ju und 2 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben.
Abstract (Originalsprache)
Objective
Cerebrovascular diseases remain a leading cause of mortality and disability worldwide. Despite significant advances in acute interventions such as thrombolysis, endovascular therapy, and neurocritical care, effective neuroprotective strategies remain limited. Molecular hydrogen has recently attracted increasing attention due to its antioxidant, anti-inflammatory, anti-apoptotic, and neuroprotective properties. This review aims to summarize the mechanisms, experimental evidence, therapeutic effects, and future perspectives of hydrogen in cerebrovascular diseases.
Methods
A comprehensive review of studies investigating hydrogen therapy in cerebrovascular diseases was conducted, including hydrogen gas inhalation, hydrogen-rich saline, and hydrogen-rich water. We focused on delivery methods, biological mechanisms, effects on vascular risk factors, and therapeutic outcomes in experimental models such as carotid artery occlusion, ischemic brain injury, subarachnoid hemorrhage, and related conditions.
Results
Current evidence suggests that hydrogen exerts neuroprotective effects by selectively scavenging reactive oxygen species, suppressing neuroinflammation, regulating microglial polarization, inhibiting apoptosis-related signaling pathways, protecting the blood-brain barrier, and improving cerebral blood flow. In addition, hydrogen may improve major cerebrovascular risk factors, including hyperglycemia, hypertension, and hyperlipidemia. Experimental studies have demonstrated that hydrogen reduces oxidative stress, brain edema, neuronal apoptosis, infarct volume, and neurological deficits in various disease models.
Discussion
Hydrogen appears to be a promising adjunctive therapy for cerebrovascular diseases. However, current evidence is limited by inconsistent administration protocols, unclear optimal dosage and timing, and a lack of large-scale clinical trials with long-term follow-up. Future research should focus on standardized treatment strategies and rigorous clinical validation.
Zitieren
APA
Ju, S., Xie, Q., & Feng, Y. (2026). Hydrogen in Cerebrovascular Disease. Translational Neurology and Neurosurgery. https://doi.org/10.2738/tnn.2026.0008
Vancouver
Ju S, Xie Q, Feng Y. Hydrogen in Cerebrovascular Disease. Translational Neurology and Neurosurgery. 2026. doi:10.2738/tnn.2026.0008
BibTeX
@article{Ju2026,
author = {Ju, Shiqin and Xie, Qintao and Feng, Yu},
title = {Hydrogen in Cerebrovascular Disease},
journal = {Translational Neurology and Neurosurgery},
year = {2026},
doi = {10.2738/tnn.2026.0008}
}
EUVIMED